Clinical Collaboration and Funding Arrangement: Artelo Biosciences, Inc. (NASDAQ: ARTL) announces the signing of a third-party fully funded clinical research agreement to advance the evaluation of its candidate drug ART27.13 in glaucoma patients.

The research is fully funded by the partner, with Artelo providing the drug compound and R&D support. This model helps biotech companies advance clinical validation of pipeline drugs without significantly increasing cash flow pressure. **Background of the Glaucoma Treatment Market** Glaucoma, as the leading cause of irreversible blindness worldwide, affects over 80 millions patients. Current treatment methods mainly focus on intraocular pressure-lowering drugs, but about 20% of patients have insufficient response to existing therapies. In recent years, novel mechanisms such as cannabinoid receptor modulators have gradually become one of the research directions for neuroprotective glaucoma treatments. Industry analysis shows that the global glaucoma drug treatment market is expected to reach tens of billions of dollars by 2030, with clear clinical demand for innovative therapies. **Drug Mechanism and R&D Progress** ART27.13 is a selective cannabinoid CB2 receptor agonist. Preclinical studies indicate it may slow retinal ganglion cell apoptosis by inhibiting neuroinflammation and oxidative stress. The drug has previously undergone clinical research for cancer-related anorexia, and its expansion to ophthalmic indications demonstrates its multi-target potential. If the glaucoma clinical study yields positive data, it will provide key support for the subsequent value enhancement of the drug. **Market Impact and Subsequent Milestones** Driven by this news, Artelo's stock showed active trading in pre-market sessions. Analysts pointed out that for small-cap biotech companies, fully funded clinical collaborations by third parties not only reduce R&D risk but are also seen as external recognition of the drug's potential. Subsequent market focus will be on patient enrollment progress and the timing of interim data readouts. Industry tracking shows that Phase II clinical studies of glaucoma drugs typically take 12-18 months to complete.